“We continue to feel confident about the peak sales.”

In context

“e next steps here. Perhaps a timeline that you anticipate for this? And should we think that this could ultimately result in some form of royalty payments from Pfizer to GSK? And then, on PENBRAYA, how does the recent ACIP recommendation set against your expectations for the sales ramp and peak potential for this vaccine? If the vaccine is effectively only used for dose two of three, does that significantly reduce the commercial opportunity you had anticipated for the vaccine? Doug Lankler: It's very, very early stages with respect to the RSV litigation. We have patents, we feel strongly about our own intellectual property. And it's certainly too early to say whether one party or the other will be required to pay any royalties or otherwise. Very early stages in that regard. Angela Hwang: We continue to feel confident about the peak sales. The reason is that, right now, we have the first set of recommendations, but the ACIP has also told us that we will have the opportunity again to come back next year when we have additional data, which is when we will have the opportunity to look at the schedule or how [indiscernible] are being – the schedule that they're being delivered today. And we'll have an opportunity again to take a look at the benefit of PENBRAYA in this population. So I feel like it's great that we have an opportunity to get out now and to begin vaccinating our teenagers. We'll have a second bite at the apple, which will allow us to achieve our peak sales. Operator: Next, we have Andrew Baum with Citi. Andrew Baum: A couple of questions. Would you comment on your stake in RVT-3101, the TL1A, pending the approval”